TAVI valve durability

Equivalent with surgery at 5 years 1*

Doctor-using-digital-tablet

Sustained improvement of haemodynamic performance1

At 5 years, the mean aortic valve area and valve gradient were equivalent in the TAVI group and the surgical (sAVR) group:
Haemodynamic performance graph
Mean aortic valve area: p=0.29; Mean valve gradient: p=0.92.
No patients receiving TAVI experienced SVD which required surgical valve replacement.

At 2-year follow-up on the PARTNER 3 Trial of TAVI in low risk patients, there was no change in mean gradient, aortic valve area or paravalvular regurgitation.4

 

See the full evidence for TAVI in low-risk severe AS patients

Minimal TAVI patients required reintervention due to SVD2

Durability data from the PARTNER 1A and 1B Trials found reinterventions with TAVI were infrequent and usually caused by reasons other than SVD. Only 20 patients (0.8%) required a reintervention of which 5 (0.2%) were due to SVD. 

Find out more about the PARTNER 1A and 1B Trials of TAVI in high-risk and inoperable patients

Freedom from SVD and BVF at 8 years3

87.2% and 96.6% (competing risk analyses) of patients receiving TAVI had freedom from SVD and BVF at 8 years, respectively. With TAVI, the incidence of SVD was 3.2% and the incidence of BVF was 0.6%.

Clinical implications

What could a TAVI referral mean for your severe AS patients?

Engineered for the future

With the expansion of SAPIEN 3 TAVI to low-risk patients, long-term durability data is of paramount importance. Clinical and echocardiographic follow-up of patients from the PARTNER 3 Trial will continue for up to 10 years.4
SAPIEN-3-aortic-valve-replacement
Manufactured using the same tissue processing as the Perimount Magna Ease which is regarded as the most durable surgical bioprosthesis the SAPIEN 3 valve was built on the proven SAPIEN platform and designed with patient needs in mind. More information can be accessed on the Edwards website.5
SAPIEN-3-aortic-valve-replacement
Manufactured using the same tissue processing as the Perimount Magna Ease which is regarded as the most durable surgical bioprosthesis the SAPIEN 3 valve was built on the proven SAPIEN platform and designed with patient needs in mind. More information can be accessed on the Edwards website.5
*Data from the PARTNER 1A Trial of TAVI in low-risk severe aortic stenosis patients.

Stay informed with our newsletter

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.     Read more

References

  • 1Mack MJ, et al. Lancet 2015;385:2477–2484.
  • 2Douglas PS, et al. JAMA Cardiol 2017; 2(11): 1197-1206.
  • 3Eltchaninoff H, et al. Eurointervention 2018; 14(3):e264-e271.
  • 4Mack MJ. Two-year clinical and echocardiographic outcomes from the PARTNER 3 low-risk randomized trial. Presented at: ACC 2020, Chicago, March 29, 2020.
  • 5Virtanen MPO, et al. J Cardiothorac Surg 2020;15(1):157.

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.

Skip to content